Status:
TERMINATED
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
Lead Sponsor:
Morphotek
Conditions:
Metastatic Colorectal Cancer
Colorectal Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate whether therapy with MORAb-004 is effective and safe in the treatment of metastatic, colorectal cancer.
Detailed Description
Tumor endothelial marker-1 also referred to as TEM-1 is expressed in the supportive tissue, as well as, on the cells within the tumor. TEM-1, which is a cell surface glycoprotein, and is expressed in ...
Eligibility Criteria
Inclusion
- Males and females \>18 years old
- Diagnosis of metastatic, colorectal cancer
- Significant medical conditions must be well-controlled and stable for at least 30 days prior to the first treatment infusion
- Be willing and able to provide written informed consent
Exclusion
- No prior treatment for metastatic colorectal cancer
- Other serious systemic diseases (bacterial or fungal)
- Clinically significant heart disease or an arrhythmia on an ECG within the past 6 months
- Known allergic reaction to monoclonal antibody therapy
Key Trial Info
Start Date :
March 27 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 20 2013
Estimated Enrollment :
154 Patients enrolled
Trial Details
Trial ID
NCT01507545
Start Date
March 27 2012
End Date
October 20 2013
Last Update
May 6 2022
Active Locations (67)
Enter a location and click search to find clinical trials sorted by distance.
1
Central Hem/Onc Medical Group, Inc.
Alhambra, California, United States, 91801
2
Comprehensive Blood and Cancer Center
Bakersfield, California, United States, 93309
3
Providence St. Joseph Medical Center-Disney Family Cancer Center
Burbank, California, United States, 91505
4
St. Jude Heritage Healthcare
Fullerton, California, United States, 92835